

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drugs in Development, 2021

<https://marketpublishers.com/r/B9D8E2A345F5EN.html>

Date: November 2021

Pages: 66

Price: US\$ 3,500.00 (Single User License)

ID: B9D8E2A345F5EN

Abstracts

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drugs in Development, 2021

SUMMARY

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulates cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 2 respectively. Similarly, the universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic Leukemia (CMML), Essential Thrombocythemia, Fibrosis, Gastric Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone-Sensitive Prostate Cancer, Hypopharyngeal Cancer, Laryngeal

Cancer, Lymphoblastic Lymphoma, Lymphoma, Mantle Cell Lymphoma, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroendocrine Tumors, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia and Relapsed Multiple Myeloma.

The latest report Bcl 2 Like Protein 1 - Drugs In Development, 2021, outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)

The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects

The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies

Involved in Therapeutics Development

AbbVie Inc

Ascenta Therapeutics Inc

Ascentage Pharma Group International

AstraZeneca Plc

Dialectic Therapeutics Inc

Sirnaomics Inc

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles

ABT-737 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0466 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DT-2216 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

navitoclax dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pelcitoclax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-369 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Hormone-Sensitive Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones

Featured News & Press Releases

Nov 04, 2021: Ascentage Pharma to release latest data from pelcitoclax including a Chinese study demonstrating complete response

Sep 13, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252) combined with osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer

Sep 08, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor Pelcitoclax (APG-1252) combined with Osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer

Aug 20, 2021: Dialectic Therapeutics receives \$14.4 million Texas Company Product

Development Research Award from the Cancer Prevention & Research Institute of Texas

May 19, 2021: Ascentage Pharma announces presentation on pelcitoclax at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 21, 2021: Ascentage Pharma to present data on pelcitoclax (APG-1252) at 2021 ASCO Annual Meeting

Apr 12, 2021: Ascentage Pharma releases preclinical data on Pelcitoclax at AACR Annual Meeting 2021

Mar 03, 2021: Dialectic Therapeutics receives FDA clearance of IND application for lead antiapoptotic protein targeted degradation (APTaD) candidate DT2216

Feb 09, 2021: AZD0466 clinical DEP program global expansion

Oct 08, 2020: Ascentage Pharma's apoptosis-targeting drug candidate granted Orphan Drug Designation by the US FDA

Jul 27, 2020: AZD0466 trial opens MD Anderson Cancer Center as a site

Jun 23, 2020: Starpharma showcased poster presentation on DEP product AZD0466 at AACR 2020

May 31, 2020: Ascentage Pharma presents latest clinical data of APG-1252 drug candidate at the 2020 ASCO

May 15, 2020: Ascentage Pharma to present data on APG-1252 at 2020 AACR Annual Meeting

Feb 26, 2020: Dialectic Therapeutics receives \$3 million seed award for product development research from the Cancer Prevention & Research Institute of Texas

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Ascenta Therapeutics Inc, 2021
Pipeline by Ascentage Pharma Group International, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Dialectic Therapeutics Inc, 2021
Pipeline by Sirnaomics Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/B9D8E2A345F5EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B9D8E2A345F5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

